Georgia's Leading Children's Hospital and the Eliava Institute Join Forces to Advance Pediatric Phage Therapy

Georgia has taken another important step toward integrating bacteriophage therapy into modern clinical practice following the signing of a strategic memorandum of cooperation between the M. Iashvili Children's Central Hospital and the George Eliava Institute of Bacteriophages, Microbiology and Virology. More than a symbolic agreement, the partnership brings together the country's largest pediatric referral hospital and one of the world's oldest and most internationally recognized phage research institutions with the shared objective of expanding access to personalized phage therapy for children facing severe bacterial infections.

Illustration taken from : https://medscriptum.org/en/when-innovation-meets-tradition-memorandum-of-cooperation-signed-between-iashvili-clinic-and-the-eliava-institute/

The agreement reflects a broader transformation taking place in infectious disease medicine. As antimicrobial resistance continues to reduce the effectiveness of conventional antibiotics, clinicians are increasingly confronted with patients for whom even the most advanced antimicrobial therapies fail to eradicate infection. Pediatric medicine presents particular challenges, as physicians must balance the need for aggressive treatment with the long-term preservation of the developing microbiome while minimizing drug-related toxicity. Within this context, bacteriophages offer a fundamentally different therapeutic approach by selectively targeting pathogenic bacteria while largely sparing beneficial microbial communities.

M. Iashvili Children's Central Hospital occupies a unique position within the Georgian healthcare system. As the country's only tertiary multidisciplinary pediatric referral center, it receives the most critically ill children from across Georgia and provides highly specialized services including pediatric oncology, hematology, neurosurgery, thoracic surgery, toxicology and complex surgical care. Because of this role, the hospital frequently encounters infections associated with prolonged hospitalization, invasive procedures, immunosuppression and multidrug-resistant pathogens, situations in which conventional antibiotic therapy may become increasingly ineffective.

For decades, the Eliava Institute has represented one of the global historical centers of bacteriophage research. Founded in 1923, the institute preserved and continuously developed phage therapy throughout periods when the approach largely disappeared from Western medicine following the widespread introduction of antibiotics. Today, its extensive bacteriophage collections, manufacturing expertise and clinical experience make it one of the few institutions worldwide capable of developing personalized phage preparations against individual bacterial isolates. The institute has also become an important international partner in collaborative research projects involving Europe, North America and the World Health Organization.

Although informal collaboration between clinicians and the Eliava Institute has existed for years, the newly signed memorandum transforms these interactions into a structured institutional partnership. This formal framework is expected to facilitate closer integration between clinical microbiology, bacteriophage characterization, patient management and scientific research while creating standardized procedures for evaluating complex infections that may benefit from phage therapy.

According to Professor Ivane Chkhaidze, Medical Director of Iashvili Clinic, one of the principal objectives is the systematic incorporation of bacteriophages into pediatric clinical practice. Rather than viewing phages solely as experimental rescue treatments administered after complete antibiotic failure, the collaboration seeks to develop individualized therapeutic strategies for patients whose infections remain difficult to control despite adherence to established clinical protocols.

This distinction reflects an important evolution in modern phage therapy. Historically, many compassionate-use cases have involved patients who had exhausted every available therapeutic option before phages were considered. Increasingly, however, researchers are investigating whether earlier integration of bacteriophages alongside surgery, source control and optimized antimicrobial therapy may improve outcomes before infections become nearly untreatable. Such questions require careful clinical evaluation, and partnerships between specialized hospitals and experienced phage centers are essential for generating the evidence needed to answer them.

The agreement also highlights the importance of precision microbiology. Unlike broad-spectrum antibiotics, bacteriophages generally infect only specific bacterial strains. Successful treatment therefore depends upon rapid pathogen identification, bacterial isolation, susceptibility testing against available phages and, when necessary, the selection or development of personalized therapeutic cocktails. Integrating these microbiological capabilities directly into clinical decision-making shortens the pathway between diagnosis and individualized treatment.

Neonatal and pediatric intensive care units may particularly benefit from these developments. Critically ill children often require prolonged hospitalization, multiple invasive procedures and repeated antibiotic exposure, all of which increase the risk of healthcare-associated infections caused by multidrug-resistant organisms. For neonates and immunocompromised children, therapeutic options can become extremely limited once bacterial resistance emerges. Establishing structured collaboration between intensive care physicians and bacteriophage specialists therefore represents an important step toward expanding future treatment possibilities.

The memorandum extends beyond patient care into education and scientific development. One of the recurring challenges identified by both institutions is the limited number of structured academic programs dedicated to bacteriophage biology and clinical phage therapy. To address this gap, the partners have already launched collaborative doctoral initiatives involving French academic institutions. These programs aim not only to train future researchers but also to strengthen the scientific foundations required for international clinical studies and peer-reviewed publications.

Academic visibility remains essential for the global acceptance of phage therapy. Although Georgia possesses more than a century of accumulated experience with bacteriophages, much of this knowledge has historically remained underrepresented in high-impact international medical journals. Expanding publication efforts will allow clinicians and researchers worldwide to evaluate Georgian experience using contemporary scientific standards while facilitating comparisons with ongoing clinical developments elsewhere in Europe and North America.

The collaboration also reflects Georgia's increasing participation in the international phage ecosystem. The Eliava Institute maintains active partnerships with European research groups and continues to engage with organizations including the World Health Organization. These international connections provide opportunities to harmonize clinical methodologies, exchange scientific expertise and contribute Georgian experience to the broader development of evidence-based phage therapy.

From a research perspective, the agreement creates opportunities extending well beyond compassionate treatment. Standardized clinical protocols, systematic microbiological characterization, prospective patient monitoring and long-term follow-up could all contribute valuable datasets for understanding treatment efficacy, bacterial resistance evolution, phage pharmacodynamics and clinical safety. Such information remains critically needed as the international community seeks to establish stronger evidence supporting phage therapy across different infectious diseases.

The partnership is also notable because it begins within pediatric medicine. Protecting children from antimicrobial resistance has implications that extend throughout an individual's lifetime. Every successful reduction in unnecessary antibiotic exposure may contribute to preserving microbial diversity while slowing the selection of resistant organisms. Although phages cannot replace antibiotics in every clinical situation, they may become valuable components of integrated antimicrobial stewardship strategies designed to preserve existing antibiotics while expanding therapeutic options.

Importantly, neither institution presents phage therapy as a universal solution. Personalized bacteriophage treatment requires specialized laboratory infrastructure, appropriate regulatory oversight, rigorous microbiological testing and careful patient selection. Clinical evidence continues to expand, but randomized controlled trials remain necessary to define precisely where phages provide the greatest benefit and how they should be integrated alongside conventional therapies.

Nevertheless, the memorandum demonstrates an important shift in perspective. Rather than preserving phage therapy as a unique scientific tradition known primarily outside Georgia, one of the country's leading pediatric hospitals has formally committed to incorporating this century-old expertise into routine clinical development. The decision recognizes bacteriophages not simply as a historical legacy of Georgian microbiology but as an active component of future precision medicine.

There is also a striking historical symmetry in this collaboration. For many years, international scientists traveled to Tbilisi to learn about bacteriophages while their clinical potential remained relatively underutilized within modern Western healthcare systems. Today, as antimicrobial resistance has become one of the defining challenges of global medicine, the accumulated expertise preserved at the Eliava Institute is attracting renewed international attention. What was once regarded as an alternative approach practiced in only a handful of countries is increasingly becoming part of mainstream scientific discussion.

The agreement between Iashvili Children's Central Hospital and the Eliava Institute therefore represents more than a national healthcare initiative. It illustrates how long-standing scientific knowledge, sustained institutional commitment and modern clinical infrastructure can converge to accelerate the responsible development of innovative antimicrobial therapies. Whether this partnership ultimately transforms pediatric infectious disease management will depend on the clinical evidence generated in the coming years, but it already marks another important milestone in the global evolution of bacteriophage therapy.

Source :

MedScriptum. When Innovation Meets Tradition: Memorandum of Cooperation Signed Between Iashvili Clinic and the Eliava Institute. https://medscriptum.org/en/when-innovation-meets-tradition-memorandum-of-cooperation-signed-between-iashvili-clinic-and-the-eliava-institute/